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Maria A. Friedlander, MPA, CT (ASCP),* Gregory J. Riely, MD, PhD,† William D. Travis, MD,*
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Introduction: The two essential requirements for pathologic spec-
imens in the era of personalized therapies for non-small cell lung
carcinoma (NSCLC) are accurate subtyping as adenocarcinoma
(ADC) versus squamous cell carcinoma (SqCC) and suitability for
EGFR and KRAS molecular testing. The aim of this study was to
comprehensively review the performance of cytologic specimens for
the above two goals in a high-volume clinical practice.
Methods: Subtyping of primary lung carcinomas by preoperative
cytology was correlated with subsequent resection diagnoses during
a 1-year period (n  192). The contribution of various clinicopath-
ologic parameters to subtyping accuracy and utilization of immuno-
histochemistry (IHC) for NSCLC subtyping were analyzed. In
addition, the performance of cytologic specimens submitted for
EGFR/KRASmolecular testing during a 1-year period (n 128) was
reviewed.
Results: Of the 192 preoperative cytology diagnoses, tumor subtype
was definitive versus favored versus unclassified in 169 (88%)
versus 15 (8%) versus 8 (4%) cases, respectively. Overall accuracy
of cytologic tumor subtyping (concordance with histology) was 93%
and accuracy of definitive diagnoses 96%. For a group of patients
with ADC and SqCC (n  165), the rate of unclassified cytologic
diagnoses was 3% and overall accuracy 96%. IHC was used for
subtyping of 9% of those cases, yielding 100% accuracy. The
strongest predictors of difficulty in subtyping of ADC and SqCC
were poor differentiation (p  0.0004), low specimen cellularity
(p  0.019), and squamous histology (p  0.003). Of 128 cytologic
specimens submitted for molecular testing, 126 (98%) were suitable
for analysis, revealing EGFR and KRAS mutations in 31 (25%) and
25 (20%) cases, respectively.
Conclusions: Cytologic subtyping of NSCLC is feasible and accu-
rate, particularly when morphologic assessment is combined with
IHC. Furthermore, routine cytologic specimens can be successfully
used for EGFR/KRAS mutation analysis. Our data strongly support
the suitability of cytologic specimens for the new therapeutic para-
digms in NSCLC.
Key Words: Non-small cell carcinoma, Adenocarcinoma, Squa-
mous cell carcinoma, Cytology, EGFR, KRAS.
(J Thorac Oncol. 2011;6: 451–458)
Non-small cell lung carcinoma (NSCLC) comprises ade-nocarcinoma (ADC) and squamous cell carcinoma
(SqCC) as the two major subtypes and several rare tumors,
including adenosquamous carcinoma, large cell carcinoma
(LCC), and pleomorphic/sarcomatoid carcinoma. Until re-
cently, subtyping of NSCLC has received little attention in
pathology because of a similar treatment strategy for all
histologic subtypes. Three major advances in thoracic medi-
cal oncology have led to a large paradigm shift in NSCLC
diagnosis, resulting in a new emphasis on accurate NSCLC
subtyping.1 First was the discovery that epidermal growth
factor receptor (EGFR) and KRAS mutations, which are
largely confined to ADC, are predictive of responsiveness
and resistance, respectively, to EGFR tyrosine kinase inhib-
itors, erlotinib and gefitinib, and accurate subtyping as ADC
versus SqCC became important for the selection of patients
for molecular testing.2 More recently, two other agents,
bevacizumab and pemetrexed, were found to have differential
toxicity and activity, respectively, in patients with SqCC
versus non-SqCC, and these agents are currently approved by
the U.S. Food and Drug Administration only for patients with
advanced non-SqCC and are excluded from use in patients
with SqCC.3–7
Approximately 60% of patients with NSCLC present
with unresectable stage IIIB or IV disease,8 where the only
pathologic material guiding systemic therapy may be small
biopsy or cytology specimens. A major advantage of cytol-
ogy is that procurement of these specimens can be accom-
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plished by minimally invasive procedures, and immediate
on-site assessment can provide real-time feedback on speci-
men adequacy and triage. It is widely recognized that cytol-
ogy has exceptional accuracy for distinguishing small cell
lung carcinoma (SCLC) from NSCLC.9,10 However, the per-
formance characteristics of cytology in NSCLC subtyping
and predictive marker testing are not well established.
The key morphologic criteria for ADC versus SqCC are
glandular architecture versus keratinization, respectively. Al-
though in the majority of cases a line of differentiation can be
readily identified by morphology, the difficulty arises in a
subset of cases, which are poorly differentiated, scant, or
poorly preserved, where distinguishing morphologic features
are not apparent. Another difficulty is presented by tumors
with mixed histology, although true adenosquamous carcino-
mas are quite rare.11 These potential morphologic limitations,
combined with the lack of clinical impact, were the reason
that a noncommittal diagnosis of NSCLC-not otherwise spec-
ified (NSCLC-NOS) was widely advocated until recently in
small specimens.12,13
In parallel with the advances in thoracic oncology,
which have made the pathologic distinction of ADC and
SqCC important, in recent years, there has been growing
evidence in pathology that immunohistochemistry (IHC) is a
powerful tool for revealing a line of differentiation as ADC
versus SqCC in morphologically unclassifiable cases.14–17
Therefore, IHC is increasingly incorporated in routine diag-
nostic practice for NSCLC subtyping, but the actual impact of
this new approach to NSCLC diagnosis on unclassified rate
and accuracy has not been reviewed.
The feasibility of NSCLC subtyping in cytologic spec-
imens, particularly before the advances in IHC, has been
controversial. A common perception is that cell dispersal and
the loss of tissue architecture prevent accurate tumor subtyp-
ing. Despite the lack of conventional architecture, there are
rigorous cytology-specific criteria. In fact, cytology provides
several notable advantages over surgical specimens for the
diagnosis of NSCLC. First, the Papanicolaou (Pap) stain, a
routine stain in cytology, was originally developed to detect
SqCC in cervical smears, and it has exquisite sensitivity for
even minimal keratinization aiding in the distinction of SqCC
from ADC (in contrast, hematoxylin and eosin [H&E]-
stained histologic sections do not have this capability). Sec-
ond, the morphologic patterns, which emerge in tumor
smears, provide a clue to a tumor subtype, which may not
even be apparent in surgical specimens. Third, cytology
smears do not have formalin-fixation artifact that can limit
interpretation of some surgical specimens; therefore, cytol-
ogy frequently provides greater nuclear and cytoplasmic
resolution than histology.
Another common concern is low cellularity, which is
sometimes viewed as an a priori limitation for using cytologic
specimens for ancillary studies, such as IHC or molecular
testing. Although some cytologic specimens (sputum and
bronchial brush/wash/lavage) are indeed typically scant, the
cellularity of fine needle aspirates (FNAs) can be similar to or
even exceed that of a small biopsy.18 Importantly, for any
cytologic specimen with cellular material in suspension (such
as FNA needle rinse), a paraffin-embedded cell pellet (cell
block) can be prepared, which can be used for IHC or
molecular studies analogous to a surgical specimen.
With the emerging clinical evidence for importance of
NSCLC subtyping and growing evidence for effectiveness of
IHC in distinguishing ADC and SqCC, in the last few years,
we have modified our cytology practice to attempt to subtype
NSCLC whenever possible by morphology and by IHC in
morphologically equivocal cases. This study represents a
comprehensive review of accuracy of this clinical practice. In
addition, we review the performance of cytologic specimens
submitted for EGFR/KRAS molecular testing.
MATERIALS AND METHODS
Cytologic/Histologic Correlation
The pathology department electronic medical record
was searched to identify all thoracic cytology specimens that
had subsequent resection for primary lung epithelial neo-
plasms (carcinomas and neuroendocrine tumors) during a
1-year period (September 1, 2006, to August 31, 2007).
Metastatic tumors were excluded. Cytologic/histologic corre-
lation was performed for same-site cytology and resection
only. To prevent sampling issues, only resected tumors
(wedge, lobectomy, and pneumonectomy) were included.
Because the focus of this study was accuracy of tumor
subtyping rather than sensitivity for tumor detection, only
cases diagnosed as positive or suspicious for epithelial neo-
plasm on cytology were included.
One hundred ninety-two paired cytology and resection
specimens were identified and formed the basis of this study.
For this study, the categories of positive and suspicious
(nearly diagnostic for malignancy but limited by scant cellu-
larity or poor cell preservation) were considered together as
positive (suspicious diagnoses were infrequent; n  6). If a
patient had more than one preoperative cytologic specimen
(such as bronchial brush, wash, and lavage), only the speci-
men with the most specific diagnosis was included for anal-
ysis. For a small subset of cases where cytology was accom-
panied by a biopsy (n  13, 7%), cytology diagnosis was
usually rendered without the knowledge of the biopsy diag-
nosis because (1) in our practice cytology and biopsy are
reviewed by different pathologists and (2) cytology is re-
viewed a day earlier due to shorter processing time.
On-site specimen adequacy assessment was provided
by cytotechnologists for all imaging-guided fine needle aspi-
rations. Slides were prepared and stained by standard meth-
odology. Routine cytologic preparations included (1) Diff
Quick (DQ)-stained air-dried smears, (2) H&E and Pap-
stained alcohol-fixed smears, (3) Pap-stained Thin Prep slides
monolayer prepared by transfer of cells in suspension, such as
FNA needle rinse or effusion fluid, from CytoLyt fixative
onto a slide by an automated processor ThinPrep 2000 and (4)
H&E-stained cell blocks (paraffin-embedded cell pellets pre-
pared by contrifugation of CytoLyt fluid after the addition of
HistoGel). The subtyping of NSCLC and the diagnosis of
other tumors followed the standard cytomorphologic crite-
ria.19 Diagnoses for cytologic specimens were rendered by
pathologists with subspecialty expertise in cytopathology.
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Resected tumors were classified and graded according to the
2004 World Health Organization (WHO) Classification of
Tumors by pathologists with subspecialty expertise in tho-
racic pathology.20
Utilization of IHC in routine clinical practice was
reviewed. During the period of this study, IHC was routinely
performed for all NSCLC for which a definite subtype could
not be determined by cytomorphology alone and which were
sufficiently cellular. Typical IHC panel included TTF-1 (No-
vocastra; Newcastle Upon Tyne, UK; dilution 1:50), p63/4A4
(Dako; dilution 1:5000), and high-molecular-weight cytoker-
atins (HMWCK)—34E12/CK903 (Dako; Carpinteria, CA;
dilution 1:800) and CK5/6 (Dako; dilution 1:200). Exact
marker panels for various cases were selected at the discre-
tion of individual pathologist but at the minimum included
TTF-1 and p63. Interpretation was based on the following
algorithm: TTF-1 negative/p63-positive/HMWCK-positive
profile was interpreted as supportive of SqCC, whereas ex-
pression of TTF-1 was interpreted as supportive of ADC. On
the basis of other studies, we allowed p63 and HMWCK
coexpression with TTF-1 for classification as ADC.21
If cytomorphology was equivocal for NSCLC subtype,
but cellularity was insufficient for IHC—a case was diag-
nosed as “NSCLC-NOS.” For cases where cytomorphology
was suggestive but not diagnostic of a NSCLC subtype, but
material was insufficient for IHC confirmation—the case was
given a “favored” diagnosis.
Data Analysis
For accuracy analysis, both definitive and favored di-
agnoses were counted as diagnostic of a tumor type. A match
for at least one component (such as cytologic diagnosis of
“ADC” for histologic diagnosis of “adenosquamous carci-
noma” or “pleomorphic carcinoma with a component of
ADC”) was counted as correct.
For analysis of binary tumor categories (such as SqCC
versus non-SqCC), cytologic diagnoses were designated as
true positive (TP)—correct cytologic diagnosis of SqCC; true
negatives (TN)—correct cytologic diagnosis of non-SqCC;
false positives (FP)—incorrect cytologic diagnosis of SqCC;
and false negatives (FN)—incorrect cytologic diagnosis of
non-SqCC. The accuracy parameters were calculated as fol-
lows: sensitivity  TP/(TP  FN), specificity  TN/(FP 
TN), positive predictive value  TP/(TP  FP), negative
predictive value  TN/(FN  TN), and accuracy (TP 
TN)/total number of cases.
Significance of associations was analyzed by two-tailed
Fisher’s exact test tests for categorical variables and unpaired
t test for continuous variables. p values of 0.05 were
considered statistically significant.
Review of EGFR/KRAS Molecular Testing on
Cytologic Specimens
For review of molecular testing on cytologic speci-
mens, we performed a separate search of the pathology
department medical records to identify all cytologic speci-
mens submitted to the Diagnostic Molecular Pathology Lab-
oratory at Memorial Sloan-Kettering Cancer Center (New
York City, NY) for EGFR/KRAS mutation testing during a
1-year period (January 1, 2009, to December 31, 2009).
Typically, DNA was extracted from 5-m-thick sections cut
from the paraffin-embedded cell blocks (median number of
sections was 14). Only cell blocks subjectively judged by a
pathologist as “adequate” (easily identifiable tumor cells by
light microscopy, with tumor cells representing at least 25%
of overall cellularity22) were submitted for testing, although
in rare cases a lower proportion of tumor cells was accepted.
Testing for EGFR exon 19 deletion mutations, EGFR exon 21
L858R point mutations, and KRAS codon 12 and 13 point
mutations was performed as described previously.23,24
Approval
This study was performed with the approval of the
Institutional Review Board of Memorial Sloan-Kettering
Cancer Center.
RESULTS
Specimen and Patient Characteristics
Cytologic specimens (n  192) included transthoracic
FNAs (n  181), exfoliative specimens (bronchial brush/
wash/lavage) (n  10), and transbronchial FNA (n  1). The
underrepresentation of bronchial specimens and the lack of
pleural effusion and sputum specimens in this series can be
explained by selection for cases with subsequent resection
and, therefore, limited representation of patients with ad-
vanced disease. Concurrent biopsy was obtained in addition
to cytology for 13 (7%) patients. Resected specimens in-
cluded wedge resections (n  64), lobectomies (n  120),
and pneumonectomies (n  8). Patient demographics were
M:F ratio: 1:1.8, average age: 68 years, and age range: 42–86
years.
Feasibility and Accuracy of Tumor Subtyping in
Cytology
Of 192 cytologic specimens, definitive versus favored
versus unclassified carcinoma subtypes were diagnosed for
169 (88%) versus 15 (8%) versus 8 (4%) cases, respectively.
The rate of unclassified diagnoses for patients with ADC and
SqCC as a group was 3% (5/165 cases). Patients with ADC
were more likely to have definitive subtyping by cytology
than patients with SqCC (93% versus 74%, respectively; p 
0.008) (Table 1).
Cytologic/histologic correlation for patients with a spe-
cific tumor subtype diagnosed by both cytology and histology
(n  183) (Table 2) revealed that 171 cytologic diagnoses
were concordant with histology (overall accuracy 93%). Dis-
crepant diagnoses (n  12) included three cytologic diag-
noses of “ADC,” which were reclassified as SqCC on resec-
tion, three “SqCC” reclassified as ADC, and one “carcinoid
tumor” reclassified as ADC (a rare but well-known pitfall for
carcinoid tumors with glandular-like architecture).25 All re-
maining discrepancies were in the large cell histologic cate-
gory, including three LCCs and two large cell neuroendocrine
carcinomas, all of which were subtyped as ADC on cytology
based on evidence of glandular features in cytologic prepa-
rations (see Discussion section). The eight cases with “un-
classified carcinoma” or “NSCLC-NOS” diagnoses in cytol-
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ogy included pleomorphic carcinomas (n  2), necrotic
carcinoma, which remained unclassified on resection (n 1),
and cytologic specimens with insufficient cellularity for fur-
ther characterization by IHC (n  5).
While overall accuracy (concordance with histologic di-
agnosis) of cytologic tumor subtyping was 93%, the accuracy of
definitive diagnoses was 96%. For a group of patients with
histologic diagnosis of ADC and SqCC (n  165), overall
accuracy was 96%, and accuracy of definitive diagnoses was
99%. Definitive cytologic diagnoses of ADC or SqCC had
positive predictive values for correct tumor type of 96% and
94%, respectively. For analysis of binary categories (Table 3),
accuracy of cytology for the distinction of SCLC versus NSCLC
was 100%, SqCC versus non-SqCC 97%, and ADC versus
non-ADC 93%. Diagnosis of SqCC had lower sensitivity than
ADC (87% versus 98%, respectively; p  0.037) but higher
specificity (98% versus 79%, respectively; p  0.0001).
Clinicopathologic Factors Contributing to the
Difficulty of NSCLC Subtyping in Cytology
For a group of patients with resection diagnosis of ADC
and SqCC, clinicopathologic factors associated with difficulty in
assigning correct definitive subtype by preoperative cytology are
summarized in Table 4. They included low specimen cellularity
(p 0.019) and exfoliative (bronchial brush/wash/lavage) rather
than FNA specimen type (p  0.037), consistent with lower
TABLE 1. Frequency of Definitive vs. Favored vs. Unclassified Tumor Subtypes in Cytology
Cytology
Histology
All Tumors Combined
(n  192)
Adenocarcinoma
(n  142)
Squamous Cell Carcinoma
(n  23)
Adenocarcinoma  Squamous Cell
Carcinoma Combined (n  165)
Definitive subtype 169 (88%) 133 (93%) 17 (74%) 150 (91%)
Favored subtype 15 (8%) 5 (4%) 5 (22%) 10 (6%)
Unclassified 8 (4%) 4 (3%) 1 (4%) 5 (3%)
TABLE 2. Correlation of Cytologic (Preoperative) vs. Histologic (Postoperative) Diagnoses
Cytology
Histology
ADC SqCC Ad-Sqa PCb LCC LCNEC Carcinoid SCLC
Unclassified
Carcinomac Total
ADC 132 1 1 2 2 2 1 1 142
NSCLC, favor ADC 3 2 1 6
SqCC 1 16 1 18
NSCLC, favor SqCC 2 3 5
SCLC or NE neo 7 2 9
Favor SCLC or NE neo 3 1 4
Unclassified carcinomad 4 1 2 1 8
Total 142 23 2 4 3 2 11 3 2 192
Green shading—concordant cytology/histology; red shading—discordant cytology/histology; and gray shading—unclassified by cytology and/or
histology.
a A predominant component of Ad-Sq carcinoma was sampled by cytology specimen and was correctly identified.
b Both pleomorphic carcinomas had a component of ADC, which was correctly identified by cytology.
c “Unclassified” histologic category includes two carcinomas with extensive necrosis and only rare viable tumor cells limiting further classification. One
case had cytologic features diagnostic of ADC, but only minimal viable tumor remained in resected specimen after neoadjuvant therapy, preventing histologic
classification.
d “Unclassified” cytologic category includes diagnoses of “NSCLC-not otherwise specified (NSCLC-NOS)” or “Carcinoma-not otherwise specified.”
ADC, adenocarcinoma; SqCC, squamous cell carcinoma; Ad-Sq, adenosquamous carcinoma; PC, pleomorphic carcinoma; LCC, large cell carcinoma;
LCNEC, large cell neuroendocrine carcinoma; SCLC, small cell lung carcinoma; NSCLC, non-small cell lung carcinoma; NE neo, neuroendocrine neoplasm
(included tumors diagnosed as carcinoid tumor, NE carcinoma, NE neoplasm, and carcinoma with NE features); NOS, not otherwise specified.
TABLE 3. Sensitivity and Specificity of Cytologic Tumor Subtyping
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
PPV,a %
(95% CI)
NPV, %
(95% CI)
Accuracy, %
(95% CI)
SCLC vs. non-SCLC 100 (29.2–100) 100 (97.9–100) 100 (29.2–100) 100 (97.9–100) 100 (98.1–100)
Squamous vs. nonsquamous 87 (66.4–97.2) 98 (94.6–99.6) 87 (66.4–97.2) 98 (94.6–99.6) 97 (93.2–98.6)
Adenocarcinoma vs. nonadenocarcinoma 98 (93.9–99.6) 79 (63.2–89.7) 94 (88.7–97.2) 92 (77.5–98.3) 93 (89.1–96.3)
Analysis performed for all tumors with at least favored tumor subtype diagnosed by cytology and histology (n  183). See Materials and Methods section
for details.
a PPVs for definitive cytologic diagnoses of squamous cell carcinoma and adenocarcinoma were 94% and 96%, respectively.
CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; SCLC, small cell lung carcinoma.
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cellularity of the former specimens. The strongest predictor for
difficulty in NSCLC subtyping was poor differentiation (p 
0.0004), as determined by the grade of the resected tumor. This
analysis shows a greater difficulty with correct definitive iden-
tification of SqCC compared with ADC (70% versus 93%,
respectively; p  0.003), as also reflected by fewer definitive
diagnoses (Table 1) and lower sensitivity (Table 3) for SqCC
compared with ADC.
Accuracy of Subtyping Aided by IHC
As summarized in Table 5, for a group of patients with
ADC and SqCC, morphologic features alone were sufficient
to identify a tumor subtype (as definitive or favored) in the
majority of cytologic specimens (146/165; 88%). Fourteen of
165 cases (9%) could not be subtyped by morphology, but after
analysis with IHC, a tumor subtype was identified (based on the
algorithm described in the Materials and Methods section).
Histologic correlation revealed that 100% of IHC-aided diag-
noses were correct, whereas morphologic diagnoses were 96%
correct. Five of 165 cases (3%) could not be subtyped by
morphology, but the cellularity was insufficient for IHC, and the
diagnoses remained unclassified (NSCLC-NOS).
Feasibility of EGFR/KRAS Molecular Testing on
Cytologic Specimens
Because molecular testing on cytology is typically
requested for patients with advanced disease, this analysis
was performed on a different cohort of patients than the one
used for the above cytologic/histologic correlation. As sum-
marized in Table 6, cytologic specimens submitted for mo-
lecular testing during the study period (n  128) included
transthoracic and transbronchial FNAs (n  67), extrathoracic
FNAs (n  29), pleural effusions (n  29), and bronchial
brush/wash specimens (n  3). Of these, 126 (98%) were
suitable for EGFR/KRAS testing, whereas two cases were not
analyzable due to PCR failure (both failures were from poorly
preserved specimens submitted from outside institutions). Of
126 analyzable samples, EGFR mutations were identified in 31
(25%) and KRAS mutations in 25 (20%) cases.
DISCUSSION
We confirm prior observations that cytology has excep-
tional accuracy for the distinction of SCLC versus NSCLC
(100%). We also find that cytologic subtyping of ADC versus
SqCC in a practice with routine utilization of IHC is highly
feasible (3% unclassified rate) and accurate (96% concor-
dance with resection diagnosis). In this series, IHC was used
to subtype 9% of NSCLC that would otherwise be diagnosed
as NSCLC-NOS by morphology, reflecting a significant re-
duction in this category as a result of IHC. Although there
were rare morphologic misclassifications, the diagnoses con-
firmed by IHC had 100% accuracy. Of note, only a small
TABLE 4. Clinicopathologic Factors Contributing to
Difficulty of Cytologic Subtyping of Adenocarcinoma and
Squamous Cell Carcinoma
Correct
Definitive
Subtyping
(n  148)
Difficulty in
Subtypinga
(n  17) pb
Age: mean (range) 68 (42–86) 66 (53–86) 0.756
Gender
Male 43 (86%) 7 (14%)
Female 105 (91%) 10 (9%) 0.402
Specimen type
FNA 143 (91%) 14 (9%) 0.037c
Exfoliative 5 (62%) 3 (38%)
Specimen cellularityd
Low 51 (82%) 11 (18%) 0.019c
High 97 (94%) 6 (6%)
Differentiatione
Well-moderately differentiated 128 (87%) 8 (47%) 0.0004c
Poorly differentiated 20 (13%) 9 (53%)
Histologic diagnosis
Adenocarcinoma 132 (93%) 10 (7%) 0.003c
Squamous cell carcinoma 16 (70%) 7 (30%)
Analysis performed for cases with final (resection) diagnosis of adenocarcinoma
and squamous cell carcinoma (n  165).
a “Difficulty in subtyping” category includes cases that were incorrectly classified
(n  6), unclassified (n  5), or underclassified/subtype favored (n  6) by cytology.
b Fisher’s exact test tests or unpaired t test.
c Considered significant (p  0.05).
d Cellularity was defined by the presence (high) or absence (low) of cell block
material.
e Grade of differentiation was based on resected specimens.
FNA, fine needle aspirates.
TABLE 5. Frequency and Accuracy of Morphologic vs.
Immunohistochemistry-Aided Diagnoses of Adenocarcinoma
and Squamous Cell Carcinoma in Cytology
Frequency Accuracy
Diagnosis based on morphology 146 (88%) 96%
Diagnosis based on IHC 14 (9%) 100%
Diagnosis that needs IHC but cellularity
insufficient (diagnosis: NSCLC-NOS)
5 (3%) na
Analysis performed for cases with final (resection) diagnosis of adenocarcinoma
and squamous cell carcinoma (n  165).
IHC, immunohistochemistry; na, nonapplicable; NSCLC, non-small cell lung
carcinoma; NOS, not otherwise specified.
TABLE 6. Suitability of Cytologic Specimens for EGFR and
KRAS Mutational Analysis: Review of Specimens Submitted
for Molecular Testing during 1-yr Period (n  128)
N (%)
Types of cytology specimens tested
Fine needle aspirates, transthoracic and transbronchial 67 (52)
Fine needle aspirates, extrathoracic 29 (23)
Pleural effusions 29 (23)
Bronchial brush/wash/lavage 3 (2)
Suitability for analysis
Suitable 126 (98)
Unsuitable 2 (2)
Frequency of mutations
EGFR mutant 31 (25)
KRAS mutant 25 (20)
No EGFR/KRAS mutations 70 (55)
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subset (13%) of cytologic specimens in this series was ac-
companied by a concurrent small biopsy; therefore, a separate
study will be needed to make a direct comparison of efficacy
and accuracy of NSCLC subtyping between cytology and
small biopsy.
We find that the diagnosis of SqCC has a very high
specificity (98%), indicating that false-positive diagnoses are
rare, but the sensitivity for SqCC is lower than that of ADC
(87% versus 98%, respectively), indicating that SqCC is
underdiagnosed compared with ADC. Interestingly, several
earlier studies, which contained predominantly broncho-
scopic specimens, reported lower sensitivity for ADC rather
than SqCC.26,27 This difference may be due to the predomi-
nance of peripheral SqCC (sampled by transthoracic FNAs)
in this series over central SqCC (sampled by bronchoscopic
techniques) in prior studies: peripheral SqCC are generally
less keratinizing than central SqCC and, therefore, more
difficult to classify correctly by morphology.28–30 Another
potential contributing factor is the changing epidemiology of
NSCLC, where SqCC is becoming an uncommon tumor type
in North America (SqCC represented 12% of specimens in
this study), and this may contribute to underrecognition of
SqCC. Despite the lower sensitivity, the overall accuracy of
SqCC versus non-SqCC diagnoses is high (97%), supporting
that cytology is suitable for guiding the therapeutic decisions
based on these binary categories.
In contrast to SqCC, we find that the issue with cyto-
logic diagnosis of ADC is with lower specificity (79%).
Rather than misdiagnoses of SqCC as ADC, the lack of
specificity is in large part due to tumors that are classified as
ADC in cytology and LCC in resection; and as discussed
next, we favor that these do not represent true misdiagnoses.
LCC is defined in the 2004 WHO Classification of Tumors as
NSCLC lacking clear evidence of glandular or squamous
differentiation by light microscopy after the entire tumor has
been examined20 (therefore, this definition is not applicable to
cytology or small biopsy, where unclassified NSCLC is
designated as NSCLC-NOS rather than LCC20,31). Although
the WHO definition of LCC is based on light microscopy, it
is long known that by electron microscopy32,33 and more
recently by IHC34,35 a line of differentiation as ADC versus
SqCC can be readily revealed in the majority of LCC. All
LCC (n  3) in this study were diagnosed cytologically as
ADC based on evidence of glandular differentiation, which
was inapparent in histology. Even though histologic diagno-
sis is considered a gold standard in cytologic/histologic cor-
relation studies, in this instance, rather than representing an
“incorrect” diagnosis, discordance was due to cytology al-
lowing a more specific diagnosis because cytologic prepara-
tions preserved more identifiable features of differentiation
than histology.
Only 3% of NSCLC in this study were unclassified by
cytology, whereas a wide-range NSCLC-NOS frequency (8–
37%) has been previously reported.12,36,37 Similarly, com-
pared with ADC/SqCC subtyping accuracy of 96% in this
study, a wide range of typing accuracy (64–98%) has been
reported.27,29,30,38–43 There are three main factors that may
explain the variability in the reported feasibility and accuracy
of NSCLC subtyping.
1. Utilization of IHC: This is becoming routine for
NSCLC subtyping in clinical practice, whereas most
prior studies that reported higher rates of unclassified
NSCLC and lower accuracy were based largely on
morphology alone. Recent studies have demonstrated
that IHC can effectively reveal the line of differentia-
tion in small specimens originally diagnosed as
NSCLC-NOS16,17,44 and that IHC-aided diagnoses show
a greater interobserver agreement than morphologic
diagnoses.17 In this study, we show the impact of IHC
in actual clinical practice—IHC reduced the rate of
unclassified NSCLC by 9% and increased accuracy
over morphologic diagnoses.
2. Cytologic specimen type/diagnostic procedure: We
show that accuracy of NSCLC subtyping was higher for
FNAs than exfoliative specimens, reflecting higher cel-
lularity of the former specimens. Therefore, studies
dominated by exfoliative cytology (or sputums) can be
expected to have lower accuracy of NSCLC subtyping
than this study, in which the majority of specimens are
transthoracic FNAs. In addition, because this is a sur-
gical series, consisting of lower stage tumors, studies of
advanced NSCLC can be anticipated to have a higher
rate of difficult-to-classify tumors because poorly dif-
ferentiated tumors (which are the main culprit for un-
classified cytology) are overrepresented in advanced
disease.45
3. Utilization of on-site immediate adequacy assessment:
This practice is not universal, but at our institution, it is
performed for every imaging-guided FNA. This prac-
tice has been previously shown to significantly increase
adequacy, diagnostic accuracy, and cost-effectiveness
of thoracic cytology.46,47 On-site assessment ensures
optimal cellularity, which is essential for accurate
NSCLC subtyping (and is a critical consideration for
ensuring sufficiency for predictive marker testing.)
In a recent review of the California Cancer Registry, it was
reported that NSCLC-NOS represents 22% of pathologic (32%
of cytologic and 19% of histologic) diagnoses of NSCLC and
that there has been a substantial increase in this diagnosis
between 1989 and 2006.37 The aforementioned parameters (uti-
lization of IHC, specimen type/diagnostic procedure, and on-site
assessment) were not reported, precluding a direct comparison
with the results of this study. We suggest that at least in part the
high rate of NSCLC-NOS in recent years reflects a “practice
trend,” in which a generic diagnosis of NSCLC-NOS was
widely encouraged in pathology,13 and IHC was not yet widely
used to classify difficult cases. Similar to our findings, there have
been several studies before the emergence of the “NSCLC-NOS
trend,” which showed high feasibility and accuracy of cytologic
subtyping of NSCLC, even in pre-IHC era.38,40,42,48 We predict
that in combination with morphologic criteria, utilization of
IHC for difficult cases and greater awareness of clinical
impact will lead to a substantial decline in the rate of
NSCLC-NOS in the coming years. Nevertheless, this study
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represents a single-institution experience, where cytology is
practiced in a subspecialty setting, and the detailed data from
other institutions will be needed to assess the experience with
NSCLC subtyping in different practice settings at the time of the
“paradigm shift” in the approach to NSCLC diagnosis.
An important consideration is a potential impact of the
new approach to NSCLC diagnosis on the clinical outcomes
data, particularly the treatment-by-histology interaction,
which was established based on specimens diagnosed largely
by light microscopy alone.1 As discussed earlier, this and
several recent studies show that IHC substantially reduces the
rate of unclassified NSCLC,16,17 while increasing the accu-
racy and interobserver agreement between pathologists.17
How the more specific, accurate, and reproducible subtyping
of advanced NSCLC will affect the clinical correlation stud-
ies will require empirical clinical data. Standardized criteria
for classification of NSCLC in small biopsies and cytology
specimens, which incorporates the utilization of IHC, are
being proposed for the first time in a new International
Association for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society Classification.31 This
should help standardize terminology and criteria and hope-
fully will be incorporated into future clinical trials.
The optimal IHC algorithm for NSCLC subtyping is
not firmly established. We find that our routine panel (which
includes TTF-1, p63, and HMWCK) performed well in spec-
imens with sufficient cellularity. Nevertheless, what constitutes
a minimal panel with greatest accuracy needs to be assessed in
focused studies. Several newer markers, including Desmocollin-
335 and micro-RNA (hsa-miR-205)44,49 have been suggested to
distinguish SqCC from ADC, but their utility compared with
standard markers needs to be evaluated further.
Finally, we find that in a large screen of various
cytologic specimens (FNAs, effusions, and exfoliative spec-
imens) submitted for EGFR/KRAS testing, 98% of samples
were suitable for analysis. Because the specimens were sub-
mitted for testing only if an adequate cell block was available
(as determined by a pathologist’s triage), the actual rate of
adequacy for molecular testing in consecutive specimens is
not reflected by this analysis and needs further study. Based
on a recent study of patients enrolled in a rebiopsy protocol
at our institution, 79% of FNAs and 89% of core biopsies
were suitable for molecular testing,50 but further studies are
needed to define the criteria for minimal cellularity require-
ments and to establish optimal parameters for specimen
procurement. We can conclude that testing is feasible and that
specimens subjectively interpreted as “adequate” by pathol-
ogists yield sufficient DNA for mutational analysis, with only
rare exceptions, which is in agreement with several other
studies.22,50–52 The rate of EGFR and KRAS mutations de-
tected in cytologic specimens is comparable with the rate
detected in surgical specimens at our institution.53
CONCLUSIONS
To our knowledge, this is the largest cytologic/histo-
logic correlation study with a focus on accuracy of NSCLC
subtyping in modern pathology practice, where IHC is rou-
tinely used for subtyping of morphologically unclassifiable
NSCLC. In addition, this is the largest review of utilization of
cytologic specimens for EGFR/KRAS molecular analysis. We
find that cytologic subtyping of ADC and SqCC is highly
feasible (unclassified rate 3%) and accurate (overall accuracy
96% and accuracy for IHC-aided diagnoses 100%). Further-
more, various cytologic specimens are suitable for EGFR/
KRAS molecular testing, although precise guidelines for min-
imal cellularity requirements need further study. We suggest
that the approach to NSCLC diagnosis in the era of histology
and predictive marker-based therapeutic decisions need not
shift to more invasive surgical procedures as has been sug-
gested54 and that cytologic specimens, when sufficiently cel-
lular, can provide not only accurate diagnosis but also ade-
quate material for molecular testing.
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